Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Researchers conducted a two-part study using real-world data and expert consensus to better understand the risk of driving impairments following CAR-T therapy in multiple myeloma (MM). Their analysis demonstrated that driving restrictions following Week 4 after CAR T-cell therapy in MM do not appear to be universally indicated and may be better determined on a case-by-case basis with the treating physician and/or neurology consultant.